XERS
Xeris Biopharma Holdings, Inc.
XERS lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
XERS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Strong |
XERS's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
XERS PE Valuation
XERS has no meaningful PE right now: it lost money over the past year.
XERS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for XERS, with profitability improving. However, they disagree widely on these estimates.
XERS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.34 | — |
| Q3 2026 | -$0.04 | +$0.05 |
| Q2 2026 | -$0.10 | +$0.10 |
| Q1 2026 | $0.07 | +$0.36 |
| Q4 2025 | $0.00 | +$0.37 |
| Q3 2025 | -$0.09 | +$0.36 |
| Q2 2025 | -$0.20 | +$0.23 |
| Q1 2025 | -$0.29 | +$0.18 |
| Q4 2024 | -$0.37 | +$0.08 |
XERS is still losing money, but far less than before: $0.04 per share over the past year, against $4.80 at its worst in late 2019.
XERS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $107.2M | +44% |
| Q2 2026 | $92.1M | +29% |
| Q1 2026 | $83.1M | +38% |
| Q4 2025 | $85.8M | +43% |
| Q3 2025 | $74.4M | +37% |
| Q2 2025 | $71.5M | +49% |
| Q1 2025 | $60.1M | +48% |
| Q4 2024 | $60.1M | +35% |
XERS's revenue has grown year over year every quarter since late 2020: $107M last quarter, up 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +6.7 points |
| Q2 2026 | 5.6% | -0.6 points |
| Q1 2026 | 9.5% | +15 points |
| Q4 2025 | 20% | +17 points |
| Q3 2025 | 9.1% | +33 points |
| Q2 2025 | 6.3% | +23 points |
| Q1 2025 | -5.1% | +30 points |
| Q4 2024 | 2.8% | +25 points |
XERS's operating margin was 16% last quarter, up 6.7 points from the same quarter a year ago, near the top of its range since 2019.
XERS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35.5M | +92% |
| Q2 2026 | $8.3M | +4440% |
| Q1 2026 | $9.9M | +$19.9M |
| Q4 2025 | $20M | +915% |
| Q3 2025 | $18.4M | +$26.7M |
| Q2 2025 | $182K | +$10.5M |
| Q1 2025 | -$10M | +$10.3M |
| Q4 2024 | $2M | -74% |
XERS has burned cash in most quarters: $74M over the past year, about seven times what it generated the year before.
XERS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.9% | +17.1M shares |
| 1 year | +6.9% | +12.3M shares |
| 3 years | +38% | +51.9M shares |
| 5 years | +186% | +124M shares |
| Available history | +603% | +163M shares |
XERS has 190M diluted shares, up 6.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | $365,000 |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $63,000 |
| Q4 2019 | — |
XERS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 4.2x | High |
| Q3 2025 | 11.5x | High |
XERS's net debt is about 1.2 years of its operating earnings (EBITDA), down from 12 years a year ago.
XERS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 85.9 | Overbought |
| Stochastic | 93.8 | Overbought |
XERS's weekly RSI is 86 (overbought) and its Stochastic is 94 (overbought).
XERS PE vs Healthcare Sector
| Metric | XERS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XERS has no meaningful PE right now: it lost money over the past year.
XERS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.5 | 45% above |
| 20 week MA | $9.57 | 74% above |
| 50 week MA | $7.79 | 114% above |
| 100 week MA | $6.68 | 149% above |
| 200 week MA | $4.49 | 271% above |
XERS is in an uptrend: it's above all five of its weekly moving averages, and 271% above its 200-week average.
XERS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.45 | $5.45 | -27% |
| 2021 | $5.45 | $2.59 | -52% |
| 2022 | $2.59 | $1.26 | -51% |
| 2023 | $1.26 | $2.35 | +87% |
| 2024 | $2.35 | $3.43 | +46% |
| 2025 | $3.43 | $7.37 | +115% |
| 2026 YTD | $7.37 | $16.7 | +126% |
XERS's yearly returns have swung widely, from +115% in 2025 to −52% in 2021. It's up 126% so far in 2026.